Dicerna Pharmaceuticals (NASDAQ:DRNA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday.
According to Zacks, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
A number of other analysts also recently weighed in on DRNA. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. SunTrust Banks initiated coverage on Dicerna Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $13.00 price objective for the company. BidaskClub downgraded Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Evercore ISI initiated coverage on Dicerna Pharmaceuticals in a research report on Tuesday, January 16th. They set an “outperform” rating and a $14.00 price objective for the company. Finally, Chardan Capital restated a “neutral” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $10.05.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.22). The company had revenue of $0.47 million for the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The business’s revenue for the quarter was up 192.6% on a year-over-year basis. During the same period last year, the firm posted ($0.68) EPS. sell-side analysts forecast that Dicerna Pharmaceuticals will post -2.86 earnings per share for the current fiscal year.
In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv acquired 285,000 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The stock was acquired at an average cost of $7.00 per share, for a total transaction of $1,995,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 29.41% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the business. First Manhattan Co. bought a new position in Dicerna Pharmaceuticals in the fourth quarter valued at about $3,865,000. Vanguard Group Inc. raised its position in Dicerna Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after purchasing an additional 14,517 shares during the last quarter. Deschutes Portfolio Strategy LLC bought a new position in Dicerna Pharmaceuticals in the third quarter valued at about $575,000. Birchview Capital LP raised its position in Dicerna Pharmaceuticals by 125.0% in the third quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock valued at $259,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Northern Trust Corp raised its position in Dicerna Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 2,094 shares during the last quarter. Hedge funds and other institutional investors own 22.76% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.